Glucox Biotech (Sweden)

Recent papers from Glucox Biotech (Sweden)

1. Specific NOX4 Inhibition Preserves Mitochondrial Function and Dampens Kidney Dysfunction Following Ischemia–Reperfusion-Induced Kidney InjuryAntioxidants · 2024
2. Investigation of the Effects of a Novel NOX2 Inhibitor, GLX7013170, against Glutamate Excitotoxicity and Diabetes Insults in the RetinaPharmaceuticals · 2024
3. The selective NOX4 inhibitor GLX7013159 decreases blood glucose concentrations and human beta-cell apoptotic rates in diabetic NMRI nu/nu mice transplanted with human isletsFree Radical Research · 2023
4. Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic RetinopathyDiabetes · 2023
5. Pharmacological Inhibition of NOX4 Improves Mitochondrial Function and Survival in Human Beta-CellsBiomedicines · 2021
6. A small molecule inhibitor of Nox2 and Nox4 improves contractile function after ischemia–reperfusion in the mouse heartScientific Reports · 2021
7. The novel NADPH oxidase 4 selective inhibitor GLX7013114 counteracts human islet cell death in vitroPLoS ONE · 2018
8. The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 miceFree Radical Research · 2015
9. Scandinavian Society for Cell Toxicology – Thirty Years of Scientific PioneeringBasic & Clinical Pharmacology & Toxicology · 2014
10. The Tenth Anniversary of the Björn Ekwall Memorial FoundationAlternatives to Laboratory Animals · 2011
11. Shikonin Increases Glucose Uptake in Skeletal Muscle Cells and Improves Plasma Glucose Levels in Diabetic Goto-Kakizaki RatsPLoS ONE · 2011